Paragraph 1 I1
England, Wales and Scotland
The following substances and products, namely:—
F1Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine)
F2AP-237 (1-[4-([2E]-3-phenyl-2-propen-1-yl)-1-piperazinyl]-1-butanone) (bucinnazine)
AP-238 (1-[2,6-dimethyl-4-[2E]-3-phenyl-2-propen-1-yl]-1-piperazinyl-1-propanone)
Azaprocin (1-[3-[(E)-3-phenyl-2-propen-1-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]propan-1-one)
Bentazepam (5-phenyl-1,3,6,7,8,9-hexahydro-2H-[1]benzothieno[2,3-e][1,4]diazepin-2-one)
N-Benzyl-ethylphenidate
Bretazenil (tert-butyl-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]-pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate)
Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)
F3Brorphine
Bufotenine
1,4-Butanediol
F4Butonitazene
Cannabinol F5(not being the product specified in paragraph 10(1) or (2))
Cannabinol derivatives not being dronabinol or its stereoisomers F6(and not being the product specified in paragraph 10(1) or (2))
F7Cannabis (not being the substance specified in paragraph 9 or product specified in paragraph 10(1) or (2))
Cannabis resin F8(not being the product specified in paragraph 10(1) or (2))
Cathinone
F94’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Clobromazolam (8-bromo-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)
Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)
Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
F10Clonitazene
Coca leaf
Concentrate of poppy-straw
F11Cumyl-PeGaClone
Desalkylgidazepam (7-bromo-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Deschloroclotizolam (2-chloro-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)
F12Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)
3,4-Dichloroethylphenidate
3,4-Dichloromethylphenidate (3,4-DCMP)
Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Difludiazepam (7-chloro-5-(2,6-difluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one)
F13Diphenidine
Ephenidine
Ethyleneoxynitazene
Ethylnaphthidate
Ethylphenidate
Eticyclidine
F14Etizolam
F15Etodesnitazene (etazene)
Etonitazene
Etryptamine
F16Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)
F17Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)
Flubrotizolam (2-bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2f][1,2,4]triazolo[4,3a][1,4]diazepine)
Fluclotizolam (2-chloro-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)
Fluetizolam (2-ethyl-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)
F18Flunitazene
F19Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)
4-Fluoroethylphenidate
4-Fluoromethylphenidate
Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Fungus (of any kind) which contains psilocin or an ester of psilocin
Gamma-butyrolactone
Gidazepam (7-bromo-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-1-acetic acid hydrazide)
F203-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Isopropylphenidate (IPP or IPPD)
F21Isotonitazene
Khat
Lysergamide
Lysergide and other N-alkyl derivatives of lysergamide
F22Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Mescaline
Methcathinone
F23MethoxyphenidineF24(1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine) (methoxphenidine)
Methylclonazepam (5-(2-chlorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one)
F254-Methylmethylphenidate
Methylmorphenate
Methylnaphthidate (HDMP-28)
F26N-methyl-1-(thiophen-2-yl)propan-2-amine (methiopropamine or MPA)
Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)
F27Metodesnitazene (metazene)
Metonitazene
Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2- one)
Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)
F28Norfludiazepam (7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
para-methyl-AP-237 (1-[4-[2E]-3-(4-methylphenyl)-2-propen-1-yl]-1-piperazinyl-1-butanone)
para-nitroazaprocin (1-[3-[(E)-3-(4-nitrophenyl)-2-propen-1-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl)propan-1-one)
Propylphenidate
F29Protonitazene
Psilocin
F30Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)
Raw opium
Rilmazafone (5-([(2-aminoacetyl)amino]methyl)-1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-N,N-dimethyl-1H-1,2,4-triazole-3-carboxamide)
Rolicyclidine
Tenocyclidine
Thionordazepam (7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-thione)
(6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ALD-52)
4-Bromo-2,5-dimethoxy-a-methylphenethylamine
4’-Chloro-deschloroalprazolam (6-(4-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)
1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)
F31N-Desethyl etonitazene
N-Desethylisotonitazene
N-Desethyl protonitazene
3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)
F323,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47,700)
(6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD)
(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD)
(6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD)
N,N-Diethyltryptamine
2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol
2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg]quinolin-9-yl}methanone (LSZ)
N,N-Dimethyltryptamine
2,5-Dimethoxy-α,4-dimethylphenethylamine
N-Hydroxy-tenamphetamine
4-Methyl-aminorex
4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4’-DMAR)
2-Methyl-AP-237 (1-[2-methyl-4-[2E]-3-phenyl-2-propen-1-yl]-1-piperazinyl-1-butanone)
F33N-Piperidinyl-etonitazene (etonitazepipne)
N-Pyrrolidino-etonitazene (etoniazepyne)
N-Pyrrolidino protonitazene
Any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—
by substitution at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;
by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;
by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;
by substitution at the 2-position of the tryptamine ring system with an alkyl substituent;
the following phenethylamine derivatives, namely—
Allyl(α-methyl-3,4-methylenedioxyphenethyl)amine
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
2-Amino-1-(3,4-dimethoxyphenyl)ethanol
Benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine
4-Bromo-β,2,5-trimethoxyphenethylamine
N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine
Cyclopropylmethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
2-(1,4-Dimethoxy-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
α,α-Dimethyl-3,4-methylenedioxyphenethylamine
α,α-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
Dimethyl(α-methyl-3,4-methylenedioxyphenethyl)amine
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
4-Iodo-2,5-dimethoxy-α-methylphenethyl(dimethyl)amine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
2-Methoxyethyl(α-methyl-3,4-methylenedioxyphenethyl)amine
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
β-Methoxy-3,4-methylenedioxyphenethylamine
1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
2-(α-Methyl-3,4-methylenedioxyphenethylamino)ethanol
α-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
N-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
α-Methyl-4-(methylthio)phenethylamine
β,3,4,5-Tetramethoxyphenethylamine
β,2,5-Trimethoxy-4-methylphenethylamine;
any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an N-alkylphenethylamine, α-methylphenethylamine, an N-alkyl-α-methylphenethylamine, α-ethylphenethylamine, or an N-alkyl-α-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substitutents;
any compound (not being a compound for the time being specified in Part 2 of this Schedule) structurally derived from fentanyl by modification in any of the following ways, that is to say—
by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
by substitution in the piperidine ring with alkyl or alkenyl groups;
by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;
by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;
by replacement of the N-propionyl group by another acyl group;
any compound (not being a compound for the time being specified in Part 2 of this Schedule) structurally derived from pethidine by modification in any of the following ways, that is to say—
by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;
by formation of an N-oxide or of a quaternary base;
1-benzylpiperazine or any compound (not being a compound for the time being specified in Part 2 of this Schedule) structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in any of the following ways—
by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;
by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups;
[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1, 2, 3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone;
3-Dimethylheptyl-11-hydroxyhexahydrocannabinol;
[9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl] oxy-5, 6, 6a, 7, 8, 9, 10, 10a-octahydrophenanthridin-1-yl] acetate;
9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[c]chromen-1-ol;
Any compound structurally derived from 3-(1-naphthoyl)indole, 3-(2-naphthoyl)indole, 1H-indol-3-yl-(1-naphthyl)methane or 1H-indol-3-yl-(2-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;
Any compound structurally derived from 3-(1-naphthoyl)pyrrole or 3-(2-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;
Any compound structurally derived from 1-(1-naphthylmethylene)indene or 1-(2-naphthylmethylene)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;
Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;
any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent;
Any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;
Any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent;
Any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent;
F35Any compound (not being a compound for the time being specified in sub-paragraphs (h) to (s) above) structurally related to 1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that is to say the indole ring, the pentyl substituent, the methanone linking group and the naphthyl ring, are linked together in a similar manner, whether or not any of the sub-structures have been modified, and whether or not substituted in any of the linked sub-structures with a benzyl or phenyl group and whether or not such compound is further substituted to any extent with alkyl, alkenyl, alkoxy, halide, haloalkyl or cyano substituents and, where any of the sub-structures have been modified, the modifications of the sub-structures are limited to any of the following, that is to say—
replacement of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole, benzimidazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-c]pyridine or pyrazolo[3,4‑b]pyridine;
replacement of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl or (tetrahydropyran-4-yl)methyl;
replacement of the methanone linking group with an ethanone, carboxamide, carboxylate, methylene bridge or methine group;
replacement of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl, cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl, 1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1-amino-1-oxopropan-2-yl, 1‑hydroxy-1-oxopropan-2-yl, piperidinyl, morpholinyl, pyrrolidinyl, tetrahydropyranyl or piperazinyl;
Any compound (not being bupropion, diethylpropion, pyrovalerone or a compound for the time being specified in sub-paragraph (a) above) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways, that is to say,
by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
by substitution at the 3-position with an alkyl substituent;
by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure;
Any compound structurally derived from 2-aminopropan-1-one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say,
by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
by substitution at the 3-position with an alkyl substituent;
by substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.
Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say,
by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups;
by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group;
by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group.
1-Phenylcyclohexylamine or any compound (not being eticyclidine, ketamine, phencyclidine, rolicyclidine, tenocyclidine or tiletamine) structurally derived from 1-phenylcyclohexylamine or 2-amino-2-phenylcyclohexanone by modification in any of the following ways, that is to say,
by substitution at the nitrogen atom to any extent by alkyl, alkenyl or hydroxyalkyl groups, or replacement of the amino group with a 1-piperidyl, 1-pyrrolidyl or 1-azepyl group, whether or not the nitrogen containing ring is further substituted by one or more alkyl groups;
by substitution in the phenyl ring to any extent by amino, alkyl, hydroxy, alkoxy or halide substituents, whether or not further substituted in the phenyl ring to any extent;
by substitution in the cyclohexyl or cyclohexanone ring by one or more alkyl substituents;
by replacement of the phenyl ring with a thienyl ring.
Any compound (not being benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine) structurally derived from mescaline, 4-bromo-2,5-dimethoxy-α-methylphenethylamine, 2,5-dimethoxy-α,4-dimethylphenethylamine, N-hydroxytenamphetamine, or a compound specified in sub-paragraph (c) or (d) above, by substitution at the nitrogen atom of the amino group with a benzyl substituent, whether or not substituted in the phenyl ring of the benzyl group to any extent;
Any compound (not being a compound for the time being specified in sub-paragraph (c) above) structurally derived from 1-benzofuran, 2,3-dihydro-1-benzofuran, 1H-indole, indoline, 1H-indene, or indane by substitution in the 6-membered ring with a 2-ethylamino substituent whether or not further substituted in the ring system to any extent with alkyl, alkoxy, halide or haloalkyl substituents and whether or not substituted in the ethylamino side-chain with one or more alkyl substituents.
any compound (not being a compound for the time being specified in sub-paragraph (a) above) with a maximum molecular mass of 500 atomic mass units and structurally derived from 2-(2-benzyl-benzimidazol-1-yl)ethanamine by modification in any of the following ways, that is to say—
by substitution at the nitrogen of the ethanamine to any extent by alkyl substituents containing up to three carbon atoms or alkenyl substituents containing up to three carbon atoms or by inclusion of the nitrogen atom (and no other atoms of the side chain) in a cyclic structure;
by substitution in the phenyl ring of the benzyl system to any extent by alkyl or haloalkyl containing up to six carbon atoms, alkoxy or haloalkoxy containing up to five carbon atoms, acetyloxy, hydroxy, cyano, halogen, thioalkyl containing up to five carbon atoms or alkylsulphonyl containing up to five carbon atoms;
by substitution at the 5- or 6- positions of the benzimidazole system by nitro, acetyl, cyano, methoxy, trifluoromethyl, trifluoromethoxy or halogen substituents;
by substitution at the benzylic carbon by a methyl group;
by replacement of the benzylic carbon by a nitrogen, oxygen or sulphur atom;
by substitution in the phenyl ring of the benzyl system by an ethoxy group linked back to the phenyl ring to form a dihydrobenzofuran structure;
by replacement of the phenyl ring of the benzyl system by methylenedioxyphenyl.
Annotations
Textual amendments
- F1
Words in Sch. para. 1(a) inserted (31.5.2017) by The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 (S.I. 2017/632), arts. 1(1), 2(2)(a)
- F2
Words in Sch. 1 para. 1(a) inserted (15.1.2025) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment) (No. 2) Regulations 2024 (S.I. 2024/1369), regs. 1(1), 3(a)(i)
- F3
Word in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(a)
- F4
Word in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(b)
- F5
Words in Sch. 1 para. 1(a) inserted (1.11.2018) by The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 (S.I. 2018/1055), regs. 1(1), 9(2)(a)
- F6
Words in Sch. 1 para. 1(a) inserted (1.11.2018) by The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 (S.I. 2018/1055), regs. 1(1), 9(2)(b)
- F7
Words in Sch. 1 para. 1(a) substituted (1.11.2018) by The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 (S.I. 2018/1055), regs. 1(1), 9(2)(c)
- F8
Words in Sch. 1 para. 1(a) inserted (1.11.2018) by The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 (S.I. 2018/1055), regs. 1(1), 9(2)(d)
- F9
Words in Sch. para. 1(a) inserted (31.5.2017) by The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 (S.I. 2017/632), arts. 1(1), 2(2)(b)
- F10
Word in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(c)
- F11
Word in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(d)
- F12
Words in Sch. para. 1(a) inserted (31.5.2017) by The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 (S.I. 2017/632), arts. 1(1), 2(2)(c)
- F13
Words in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(e)
- F14
Word in Sch. para. 1(a) inserted (31.5.2017) by The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 (S.I. 2017/632), arts. 1(1), 2(2)(d)
- F15
Words in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(f)
- F16
Words in Sch. 1 para. 1(a) inserted (18.8.2021) by The Misuse of Drugs and Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Regulations 2021 (S.I. 2021/897), regs. 1(1), 3(2)(a)
- F17
Words in Sch. para. 1(a) inserted (31.5.2017) by The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 (S.I. 2017/632), arts. 1(1), 2(2)(e)
- F18
Word in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(g)
- F19
Words in Sch. 1 para. 1(a) inserted (18.8.2021) by The Misuse of Drugs and Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Regulations 2021 (S.I. 2021/897), regs. 1(1), 3(2)(b)
- F20
Words in Sch. para. 1(a) inserted (31.5.2017) by The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 (S.I. 2017/632), arts. 1(1), 2(2)(f)
- F21
Word in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(h)
- F22
Words in Sch. para. 1(a) inserted (31.5.2017) by The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 (S.I. 2017/632), arts. 1(1), 2(2)(g)
- F23
Word in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(i)
- F24
Word in Sch. 1 para. 1(a) inserted (15.1.2025) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment) (No. 2) Regulations 2024 (S.I. 2024/1369), regs. 1(1), 3(a)(ii)
- F25
Words in Sch. para. 1(a) inserted (31.5.2017) by The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 (S.I. 2017/632), arts. 1(1), 2(2)(h)
- F26
Words in Sch. 1 para. 1(a) inserted (27.11.2017) by The Misuse of Drugs (Designation) (Amendment) (No. 2) (England, Wales and Scotland) Order 2017 (S.I. 2017/1118), arts. 1(1), 2(2)
- F27
Words in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(j)
- F28
Words in Sch. 1 para. 1(a) inserted (18.8.2021) by The Misuse of Drugs and Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Regulations 2021 (S.I. 2021/897), regs. 1(1), 3(2)(c)
- F29
Word in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(k)
- F30
Words in Sch. para. 1(a) inserted (31.5.2017) by The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 (S.I. 2017/632), arts. 1(1), 2(2)(i)
- F31
Words in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(l)
- F32
Words in Sch. para. 1(a) inserted (31.5.2017) by The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2017 (S.I. 2017/632), arts. 1(1), 2(2)(j)
- F33
Words in Sch. 1 para. 1(a) inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 3(2)(m)
- F34
Sch. 1 para. 1(sa) inserted (14.12.2016) by The Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Order 2016 (S.I. 2016/1124), arts. 1(1), 2(2)
- F35
Words in Sch. 1 para. 1(sa) substituted (15.11.2019) by The Misuse of Drugs and Misuse of Drugs (Designation) (Amendment) (England, Wales and Scotland) Regulations 2019 (S.I. 2019/1362), regs. 1(1), 3
- F36
Sch. 1 para. 1(z) inserted (15.1.2025) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment) (No. 2) Regulations 2024 (S.I. 2024/1369), regs. 1(1), 3(b)
Commencement
- I1
Sch. 1 para. 1 in force at 31.5.2015, see art. 1(1)